To include your compound in the COVID-19 Resource Center, submit it here.

Tolvaptan: Phase III data

In the double-blind, placebo-controlled, international Phase III SALT-2 trial in 243 patients, tolvaptan significantly increased the average daily

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE